Fluticasone propionate HFA (Flovent® HFA) is an inhaled corticosteroid used first-line for pediatric patients with asthma that require an everyday controller medication. Flovent® HFA has established dosing for all ages and is compatible with a mask and spacer, making it the most prescribed controller inhaler for pediatric patients.
Beginning July 1, 2022, Flovent® HFA will have a preferred brand over generic designation on the Ohio Medicaid unified preferred drug list (UPDL). This is a result of fluticasone propionate generic inhaler launching into the marketplace. This transition may cause your office to receive prior authorizations from pharmacies that process the prescription for the generic medication (which is the default of most pharmacy systems). It is not necessary to submit the prior authorization; instead, communicate with the pharmacy to process the prescription for brand name Flovent® and that should result in a paid claim. This change will be highlighted on Partners For Kids July UPDL updates and additional details will be included in this document to assist pharmacies in processing the medication correctly.